CN104286876A - Oxygenuine health food - Google Patents
Oxygenuine health food Download PDFInfo
- Publication number
- CN104286876A CN104286876A CN201410581529.7A CN201410581529A CN104286876A CN 104286876 A CN104286876 A CN 104286876A CN 201410581529 A CN201410581529 A CN 201410581529A CN 104286876 A CN104286876 A CN 104286876A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- gold
- oxygen gold
- oxygenuine
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 37
- 239000002994 raw material Substances 0.000 claims abstract description 15
- KZNMRPQBBZBTSW-UHFFFAOYSA-N [Au]=O Chemical compound [Au]=O KZNMRPQBBZBTSW-UHFFFAOYSA-N 0.000 claims description 124
- 239000007788 liquid Substances 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002229 CNT20 Substances 0.000 claims description 2
- 101100007300 Caenorhabditis elegans coq-2 gene Proteins 0.000 claims description 2
- 101100449785 Mus musculus Gsx2 gene Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 20
- 230000036039 immunity Effects 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000008821 health effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 239000002211 L-ascorbic acid Substances 0.000 description 10
- 235000000069 L-ascorbic acid Nutrition 0.000 description 10
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 9
- 235000017471 coenzyme Q10 Nutrition 0.000 description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 7
- 230000004098 cellular respiration Effects 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 230000002929 anti-fatigue Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960001518 levocarnitine Drugs 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an oxygenuine health food, belonging to the technical field of health foods. Active components of the oxygenuine health food comprise the following raw materials in parts by weight: 15-25 parts of oxygenuine L-AA, 1-5 parts of oxygenuine DL-TA, 1-5 parts of oxygenuine CoQ, 1-5 parts of oxygenuine GSH, 15-25 parts of oxygenuine L-CNT, 3-8 parts of oxygenuine TRN, 1-5 parts of oxygenuine NTM, 25-35 parts of oxygenuine CLN and 40-60 parts of oxygenuine CRT. The health food disclosed by the invention has the effects of enhancing body immunity, resisting fatigue, resisting ageing, adjusting internal secretion, lowering blood pressure, lowering blood lipid, lowering blood glucose and the like and thus is a health food with excellent health effect.
Description
Technical field
The present invention relates to a kind of health food, be specifically related to a kind of that contain multiple oxygen gold, that there is health-care efficacy series food, belong to field of health care food.
Background technology
Oxygen gold is 21 century ancestral cell biology, molecular biology, the new ideas of biochemistry crossing research, it is the key intermediate of a series of participation cellular oxidation in cell, in cell mitochondrial together with oxygen chemotrophy material (sugar, fat, protein), generate energy, maintain vital movement.Because of the key energy factor that it is in cellular respiration, western scientist is by its called after " Oxygenuine " (being composited by word " oxygen " (oxygen) and " genuine " (genuine)), and China scientist is then translated as Chinese " oxygen gold ".Oxygen gold is the required nutrient of oxygen golden body (cell mitochondrial), and oxygen golden body structure function can be protected complete, and promote oxygen golden body Function, determining the quality of cellular respiration, is the mark of " cell cardio-pulmonary function ".
Oxygen golden body is international oxygen
gold lifescience association, named with its function based on its core status in cellular respiration the mitochondrial rebaptism of organelle in this century.Energy needed for eukaryotic vital movement about has 95% to be come from cell oxygen golden body.Oxygen golden body is organelle the most related with cellular respiration, and several final steps of cellular respiration carry out all wherein.It consumes the oxygen of human body more than 95%, and produces the nearly all energy of human body with the form of ATP, have the title of " cell mobility factory ".The process of life is exactly the process that energy continues to flow.In the process, the flowing of energy in body cell has been come to the process of another molecular transfer from a molecule by electronics.When a molecule provides electronics, it is just oxidized, and another molecule receiving electronics has just been reduced.This process is called cellular oxidation, also known as cellular respiration.The essence of life is energy, and energy source, in cellular oxidation, does not have life without cellular oxidation, and the essence of life process is exactly cellular oxidation.Oxygen gold opposing oxidative pressure, protection oxygen golden body structure function is complete; Repair the damage of oxygen golden body, promote oxygen golden body function; Excited oxygen golden body generates.Oxygen gold is the patron saint of oxygen golden body, is the indispensable important substance of human energy metabolism.
Cellular oxidation can produce free radical, and in organism, the free radical of certain level is that maintenance normal activities is necessary.The multiple pathology such as propagation, differentiation, apoptosis, necrosis of free radical and cell, physiological phenomenon are closely related.Under normal circumstances, the oxidative and anti-oxidative of body is among a kind of dynamic balance (oxygen weighing apparatus state), but due to a variety of causes, as impaired in some xenobiontics, ionising radiation or body self anti-oxidative defense system etc., Free Radical Level all can be made obviously to increase, oxidative and anti-oxidative is unbalance, causes oxidative pressure to damage; Excessive free radical particularly active oxygen radical, can attack the nearly all biomolecule comprising DNA, produces multiple different consequence (as at least 70 kinds of diseases such as tumour, diabetes, cardiovascular and cerebrovascular diseases, deformity and old and feeble degeneration etc.).Oxygen gold scavenging free radicals and prevent peroxidating, participating in cellular respiration, is the key intermediate in cellular oxidation, synergistic oxidation nutriment produce power; Improve the level of cell oxygen golden body zymolyte and coenzyme; Strengthen intracellular oxidation resistance.Oxygen gold is to the importance of human body as can be seen here.
Immunity of organisms, antifatigue, anti-ageing is strengthened in view of oxygen gold group has, regulate endocrine, aided blood pressure-lowering, reducing blood lipid, the effect such as hypoglycemic, be the health factor that human body needs, by dietotherapy approach appropriate supplement oxygenation gold, group will to specific crowd body
functionregulate, there is specific health care.Therefore the invention provides a kind of health food containing oxygen gold, for carrying out health care to human body, strengthening body immunity.
Summary of the invention
The object of the present invention is to provide a kind of oxygen gold health food, it has and strengthens immunity of organisms, antifatigue, anti-ageing, regulates endocrine, hypotensive, reducing blood lipid, the effect such as hypoglycemic, is the splendid health food of a kind of health-care effect.
The present invention is by the following technical solutions:
A kind of oxygen gold health food, it is characterized in that, its active component comprises the raw material of following weight portion: oxygen gold L-AA 15-25, oxygen gold DL-TA 1-5, oxygen gold CoQ 1-5, oxygen gold GSH 1-5, oxygen gold L-CNT 15-25, oxygen gold TRN 3-8, oxygen gold NTM 1-5, oxygen gold CLN 25-35, oxygen gold CRT 40-60.
Preferred as one of the present invention, its active component comprises the raw material of following weight portion: oxygen gold L-AA 18-22, oxygen gold DL-TA 1-3, oxygen gold CoQ 2-4, oxygen gold GSH 2-4, oxygen gold L-CNT 18-22, oxygen gold TRN 4-6, oxygen gold NTM 1-3, oxygen gold CLN 28-32, oxygen gold CRT 45-55.
Preferred as another kind of the present invention, its active component comprises the raw material of following weight portion: oxygen gold L-AA 20, oxygen gold DL-TA 1, oxygen gold CoQ 2, oxygen gold GSH 2, oxygen gold L-CNT 20, oxygen gold TRN 5, oxygen gold NTM 1, oxygen gold CLN 30, oxygen gold CRT 50.
Each raw material of the present invention adopts routine fashion to make tablet, capsule, oral liquid or beverage.
Oxygen gold group and major function as follows:
1, oxygen gold L-AA: have another name called L-AA (L-Ascorbic Acid), has anti-oxidant, enhancing development, develop immunitypty, promotion iron absorbs and effect such as synthesis of collagen.
2, oxygen gold DL-TA: have another name called DL-lipoic acid (DL-Thioctic acid) and there is anti-oxidant, hypoglycemic, fat-reducing, radioresistance and the effect such as to delay senility.
3, oxygen gold CoQ: have another name called ubiquinone (Coenzyme Q), plays energy-producing basic role in cell: be 1. the high efficiency electron carrier in cell mitochondrial in electron transport chain between flavoprotein and cytochromes; 2. the phosphoric acid reduction effect of ATP in auxiliary catalysis mitochondria, promotes the energy supply of cell; 3. neutralize by the free radical produced in energy generation process; 4. the integrality of retention wire Mitochondria Membrane is helped.In addition, also there is strengthening heart, reduce hypertension, antifatigue, anti-oxidant, anti-ageing and prevent the effects such as skin aging.
4, oxygen gold GSH: have another name called glutathione (Glutathione), have anti-oxidant, improve body immunity, removing toxic substances, antiallergy, protection liver and beautification function.The parkinsonism at initial stage can also be alleviated, also have good effect in treatment cornea disease and improvement function aspects.
5, oxygen gold L-CNT: have another name called levocarnitine (L-Carnitine); be mainly used in health slimming, antifatigue, adjusting blood lipid; contribute to protection and support the heart, hepatic and/or renal normal function; regulate endocrine, promote infants growth and development, the decline overcoming memory of elderly person and cognitive function, the rapid recovery that delays senility, can also help body after fatigue.
6, oxygen gold TRN: have another name called tarine (Taurine), there is promotion infant brain tissue and intelligence development, improve nerve conduction and visual function, prevent cardiovascular disease, affect the absorption of lipid, improve endocrinosity, strengthen body immunity, affect glycometabolism, suppress cataractous and develop, the function of Improving memory, maintain normal reproductive function, anti-oxidant, the effect such as delay senility.
7, oxygen gold NTM: have another name called niacinamide (Nicotinamide), its effect is the synthesis, reducing blood lipid etc. that ensure body intracellular metabolic, maintain normal neurological function, ensure sex hormone etc.
8, oxygen gold CLN: have another name called choline (Choline), have and promote brain growth and transmethylase metabolism in raising memory capability, guarantee information transmission, regulating cell apoptosis, promotion fat metabolism, promotion body and the effect reducing serum cholesterol, it still forms biomembranous important composition composition.
9, oxygen gold CRT: have another name called creatine (Creatine), it can provide quick energy supply material, increases muscle power; Accelerate amino acid whose absorption, promote the synthesis of human body protein; Acidity, alkaline matter in buffering blood, reduce the damage of these harmful substances to human body; Also there is antifatigue, short restitution.
10, oxygen gold MT: have another name called Mei Letongning (N-acetyl-5-methoxytryptamine), energy improving water flood, anti-oxidant, immunity moderation ability, protection liver, and have protective effect to DNA injury.
The experimental study of oxygen gold health food develop immunitypty
1. experiment material and grouping
Healthy female kunming mice 144, body weight 20 ± 2g, after mouse adaptability feeds 7 days, in strict accordance with the method requirement of " health food inspection and assessment technical specification ", mouse is divided at random 3 immune group, each immune group is divided into Normal group again at random, basic, normal, high dosage 3 groups, often organizes 12 mouse.Antibody-producting cell detection is carried out in immunity 1 group and serum hemolysin measures; Carbonic clearance experiment is carried out in immunity 2 groups; Immunity 3 groups is carried out Turnover of Mouse Peritoneal Macrophages and is engulfed chicken red blood cell experiment.Each control group gives physiological saline, each experimental group give respectively oxygen gold oral liquid that the present invention fills a prescription obtained 5,10,20ml/kg, once a day, gastric infusion, continuous 30 days, surveys every immune indexes.
2. laboratory apparatus and reagent
Instrument Shimadzu UV-2450 ultraviolet specrophotometer.The reagent such as reagent sheep red blood cell (SRBC) (SRBC), agarose, phenazine methosulfate (PMS) are all purchased from Ameresco company; The reagent such as RPMI1640 complete culture solution are purchased from TCI company.
3. experimental technique
The mensuration mouse peritoneal injection SRBC of 3.1 mouse antibodies cellulation numbers is after 5 days, and win eyeball and get blood, centrifuging and taking serum-dilution 100 times, carries out HD50 pH-value determination pH.Put to death mouse, take out spleen under sterile working and prepare Spleen cell suspensions, preparation method is as follows: mouse spleen Hanks liquid is washed 2 times, each centrifugal 10min(1000r/min, centrifugal radius 9.2cm), be suspended in by cell in 1ml RPMI complete culture solution, adjustment cell concentration is 3 × 10
6/ ml, makes cell suspending liquid.Then antibody-producting cell mensuration is carried out.Hanks liquid double with equivalent after epidermal cell culture base heating for dissolving is mixed, packing small test tube, often pipe 0.5ml, then in pipe, add 50 μ L10%SRBC, 25 μ L Spleen cell suspensions, be poured on the slide of brush agarose thin layer after mixing rapidly, after agar solidification, slide level is buckled and is placed on slide frame, put into CO2 incubator incubation 1.5h, then join in slide frame groove with the complement (1:8) of SA liquid dilution, after continuing incubation 1.5h, counting hemolysis plaque number.Experimental result is in table 1.
Note: control group compares,
* p< 0.01.
The india ink that 3.2 mouse carbonic clearance experiment mice intravenous injection 1:3 dilute, timing immediately after prepared Chinese ink injects, to inject after prepared Chinese ink 2,10 minutes, gets blood 20 μ L respectively, and added 2mlNa from angular vein clump
2cO
3in solution, sentence Na with ultraviolet specrophotometer at 600nm wavelength
2cO
3solution is made blank and is surveyed OD value.By sacrifice, get liver and spleen is weighed, note phagocytic index.The results are shown in Table 2.
Phagocytic index=end weight × K
1/3/ (liver weight+spleen weight) K=(logOD
1-logOD
2)/(t
2-t
1).
Note: control group compares,
* p< 0.05,
* p< 0.01.
3.3 Turnover of Mouse Peritoneal Macrophages engulf chicken red blood cell experiment mice lumbar injection 20% chicken erythrocyte suspension 1ml, and interval 30min puts to death, and is fixed on mouse plate, cut off abdominal skin, injecting normal saline 2ml, rotate mouse plate 1min, sucking-off abdominal cavity washing lotion 1ml, divides and drips on 2 slides, 37 DEG C of incubation 3min, use physiological saline rinsing, dry, fix with 1:1 acetone methanol solution, Giemsa dyes 3min, dry with distilled water rinsing, with oily mirror microscopy, calculate phagocytic rate and phagocytic index.Experimental result is in table 3.
Macrophage number × 100 of phagocytic rate (%)=the engulf phagocyte number/counting of chicken red blood cell
Phagocytic index=by engulf chicken red blood cell sum/counting macrophage number
Note: control group compares,
* p< 0.05,
* p< 0.01.
The experimental data display of table 1-3, the mouse of the basic, normal, high dosage group of oxygen gold health food of the present invention, phagocytic function and the carbonic clearance function of its macrophage obviously strengthen; The ability of the mouse bone-marrow-derived lymphocyte generation antibody of the basic, normal, high dosage group of oxygen gold health food significantly improves.These results suggest that oxygen gold health food of the present invention can strengthen nospecific immunity and the specific immune function of mouse.
The health food system nutrient prime replenisher containing oxygen gold that the art of this patent provides, belongs to replenishing vitamins and mineral matter category.Oxygen gold group all derives from domestic pharmacy unit, can directly use.Without incompatibility between raw material, human safety is not had an impact.Health food of the present invention can not alternatives to medication use.Main adaptation population is middle-aged and old immunocompromised person, tumor patient, slight Hypertension person, Hyperlipidemia person, high blood glucose person, contact radiation person, poor sleep person.Lesions of liver and kidney danger person and women breast-feeding their children, children are had to be cautious use of.
The invention has the beneficial effects as follows:
1. the present invention adopts multiple oxygen gold combination matching to make, and without incompatibility between each raw material, compatibility is reasonable, and effect is obvious.Have and strengthen immunity of organisms, antifatigue, anti-ageing, regulate endocrine, hypotensive, reducing blood lipid, the effect such as hypoglycemic.
2. health food of the present invention is safe and reliable, without any side effects, also can not produce dependence effect, is applicable to long-term taking.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in further detail.
Embodiment 1
A kind of oxygen gold health food, its active component comprises the raw material of following weight: oxygen gold L-AA 200g, oxygen gold DL-TA 10g, oxygen gold CoQ 20g, oxygen gold GSH 20g, oxygen gold L-CNT 200g, oxygen gold TRN 50g, oxygen gold NTM 10g, oxygen gold CLN 300g, oxygen gold CRT 500g.
Above-mentioned health food adds customary adjuvant and adopts conventional method to be prepared into 1000 tablets of tablets.
Embodiment 2
A kind of oxygen gold health food, its active component comprises the raw material of following weight: oxygen gold L-AA 100g, oxygen gold DL-TA 5g, oxygen gold CoQ 10g, oxygen gold GSH 10g, oxygen gold L-CNT 100g, oxygen gold TRN 25g, oxygen gold NTM 5g, oxygen gold CLN 150g, oxygen gold CRT 250g.
Above-mentioned health food adds customary adjuvant and adopts conventional method to be prepared into 1000 seed lac wafers.
Embodiment 3
A kind of oxygen gold health food, its active component comprises the raw material of following weight: oxygen gold L-AA 200g, oxygen gold DL-TA 10g, oxygen gold CoQ 20g, oxygen gold GSH 20g, oxygen gold L-CNT 200g, oxygen gold TRN 50g, oxygen gold NTM 10g, oxygen gold CLN 300g, oxygen gold CRT 500g.
Above-mentioned health food adds the auxiliary materials such as maltitol, potassium citrate, citric acid, disodium ethylene diamine tetraacetate, Sucralose, flavoring essence and adopts routine fashion to be prepared into 1000 bottles of oral liquids, every bottle of 20ml.
Embodiment 4
A kind of oxygen gold health food, its active component comprises the raw material of following weight: oxygen gold L-AA 50g, oxygen gold DL-TA 2.5g, oxygen gold CoQ 5g, oxygen gold GSH 5g, oxygen gold L-CNT 50g, oxygen gold TRN 12.5g, oxygen gold NTM 2.5g, oxygen gold CLN80g.
Above-mentioned health food adds customary adjuvant sweetener, acid flavoring, spices and essence, pigment, thickening stabilizing agent and anticorrisive agent etc. and is conventionally prepared into 1000 bottles of beverages, every bottle of 300ml.
Clinical effectiveness is tested
To hyperglycaemia, high fat of blood, hypertensive care treatment effect
Clinical data
The hyperglycaemia selecting certain hospital outpatient department to make a definite diagnosis, high fat of blood, hypertensive three high patients totally 100, the mean age is 46.5 years old, and patient is divided into five groups at random, often organizes 20 people.Wherein, the 1st group is control group, and other 2,3,4,5 groups is test group.
Methods for the treatment of
1st group of patient can not take other any medicine or food with health care at duration of test, and the 2nd group of patient takes the obtained health food of embodiment 1, once a day, and an a slice; 3rd group of patient takes the obtained health food of embodiment 2, once-a-day, one time one, 4th group of patient takes the obtained health food of embodiment 3, once-a-day, one time one bottle, 5th group of patient takes the obtained health food of embodiment 4,2 times on the one, one time one bottle, all GP TH cycles are 30 days.
Curative effect determinate standard
Recovery from illness: blood sugar, blood fat, pressure value return to normal condition;
Effective: blood sugar, blood fat, pressure value have obvious decline, but still exceed normal value;
Invalid: before and after treatment, blood sugar, blood fat, pressure value are without obvious decline.
Result of the test
Result statistics is in table 4.
Table 4 clinical test results
? | Recovery from illness example | Effective example | Invalid example | Efficient (%) |
1st group | 0 | 0 | 20 | 0 |
2nd group | 18 | 2 | 0 | 100 |
3rd group | 17 | 3 | 0 | 100 |
4th group | 19 | 1 | 0 | 100 |
5th group | 16 | 4 | 0 | 100 |
As can be seen from the above table, health food prepared by embodiment 1-4, to hyperglycaemia, hyperlipidemia and hypertension has splendid care treatment effect, and total effective rate reaches 100%.
Claims (4)
1. an oxygen gold health food, it is characterized in that, its active component comprises the raw material of following weight portion: oxygen gold L-AA 15-25, oxygen gold DL-TA 1-5, oxygen gold CoQ 1-5, oxygen gold GSH 1-5, oxygen gold L-CNT 15-25, oxygen gold TRN 3-8, oxygen gold NTM 1-5, oxygen gold CLN 25-35, oxygen gold CRT 40-60.
2. oxygen gold health food according to claim 1, it is characterized in that, its active component comprises the raw material of following weight portion: oxygen gold L-AA 18-22, oxygen gold DL-TA 1-3, oxygen gold CoQ 2-4, oxygen gold GSH 2-4, oxygen gold L-CNT 18-22, oxygen gold TRN 4-6, oxygen gold NTM 1-3, oxygen gold CLN 28-32, oxygen gold CRT 45-55.
3. oxygen gold health food according to claim 2, it is characterized in that, its active component comprises the raw material of following weight portion: oxygen gold L-AA 20, oxygen gold DL-TA 1, oxygen gold CoQ 2, oxygen gold GSH 2, oxygen gold L-CNT 20, oxygen gold TRN 5, oxygen gold NTM 1, oxygen gold CLN 30, oxygen gold CRT 50.
4. oxygen gold health food according to any one of claim 1 to 3, is characterized in that, described each raw material adopts routine fashion to make tablet, capsule, oral liquid or beverage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410581529.7A CN104286876A (en) | 2014-10-28 | 2014-10-28 | Oxygenuine health food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410581529.7A CN104286876A (en) | 2014-10-28 | 2014-10-28 | Oxygenuine health food |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104286876A true CN104286876A (en) | 2015-01-21 |
Family
ID=52307045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410581529.7A Pending CN104286876A (en) | 2014-10-28 | 2014-10-28 | Oxygenuine health food |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104286876A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102440386A (en) * | 2010-10-15 | 2012-05-09 | 胥永贵 | Full composite human body antioxidant |
-
2014
- 2014-10-28 CN CN201410581529.7A patent/CN104286876A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102440386A (en) * | 2010-10-15 | 2012-05-09 | 胥永贵 | Full composite human body antioxidant |
Non-Patent Citations (2)
Title |
---|
YOCOMODO: "《百度百科》", 29 March 2013 * |
陈吉声等: "《新编临床药物学》", 31 August 2013, 中国中医药出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080292597A1 (en) | Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases | |
CN100536878C (en) | Tianshen oral liquid with fatigue-resistance and immunoregulation action | |
CN102417544B (en) | Ziyang selenium-rich green tea selenium-containing polysaccharide, and preparation method and application thereof | |
CN103719995B (en) | A kind of collagen ceramide beverage | |
CN101296693A (en) | Endurance improver | |
CN101248880B (en) | Fatigue resistant sport drink and method of preparing the same | |
CN107440091A (en) | A kind of children's full function nutritious supplementary pharmaceutical | |
CN102578588A (en) | Combiner capable of promoting movement function and sexual function | |
CN104388236B (en) | A kind of grape wine and preparation method and application | |
Białek et al. | The biomedical role of zinc in the functioning of the human organism | |
CN104799286A (en) | Composition for improving immunity and preparation method of composition | |
CN103829340A (en) | Functional drink and preparation method thereof | |
CN103284261A (en) | Sports drink containing morinda officinalis and preparation method thereof | |
CN102688471A (en) | Compound preparation for preventing fatigue | |
CN102292082A (en) | A multivitamin/mineral formulation to combat the effects of environmental stress | |
CN101322711B (en) | Health care medicament for resisting fatigue and enhancing immunity and preparation thereof | |
CN104286876A (en) | Oxygenuine health food | |
CN103690573B (en) | A kind of natural drug composition for strengthen immunity and preparation method thereof | |
CN101317605B (en) | Novel formulating method for functional milk powder | |
CN108094990A (en) | It is a kind of to improve mental energy jelly | |
CN101443000A (en) | Xanthone derivative for the treatment of muscular disorders | |
CN102670953A (en) | Heath-care slimming liquid | |
CN102613576A (en) | Breast health and beauty nutritional tablets | |
CN112075634A (en) | Anti-aging compound nutrient containing coenzyme and bioactive hydrogen and preparation method and application thereof | |
CN108013438A (en) | A kind of health-care food contg. Chinese caterpillar fungus and its preparation process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150121 |